A recent Intensive Care digest,
as sent to subscribers

Study Type: Commentary / narrative review

Key Question: What is the pathobiology and clinical significance of airway mucus plugs in asthma and COPD, and how should they be incorporated into clinical trials and practice?

Key Findings:

• Mucus plug burden (quantified via CT bronchopulmonary segment scoring) correlates with increased exacerbations, accelerated spirometric decline, and higher mortality in COPD
• Biologic therapies in asthma have demonstrated measurable reductions in CT-quantified mucus plug burden alongside spirometric improvement, supporting mucus plugging as a treatable trait
• Standardised quantitative CT scoring methods are still maturing but are considered sufficiently developed for research and clinical integration

Clinical Relevance: For UK ICU/critical care teams managing severe asthma or COPD exacerbations, CT-quantified mucus plug burden may offer a practical phenotyping and prognostic tool, and could inform selection of biologic therapy in refractory cases.

Limitations: As a review/commentary, no primary data are presented; conclusions depend on the quality and heterogeneity of cited studies.

Study Type: Large prospective registry cohort study (observational)

Key Question: Does each additional prior exacerbation incrementally increase future exacerbation risk in bronchiectasis, and does this vary by aetiology or region?

Key Findings:

• Each prior exacerbation confers progressively higher future exacerbation risk: IRR 1.45 (×1 prior), rising to 3.56 (×4+ prior exacerbations), with no identifiable safe threshold
• A single prior hospitalisation predicted a near-fourfold increase in future severe exacerbations (IRR 3.96, 95% CI 3.71–4.22)
• The frequent exacerbator phenotype was consistent across all aetiologies and geographic regions studied

Clinical Relevance: For UK ICU/respiratory clinicians managing bronchiectasis, this challenges the binary ≥3 exacerbations/year threshold; even one prior hospitalisation substantially escalates risk, supporting earlier, more aggressive preventative intervention regardless of aetiology.

Limitations: Registry data limits causal inference, and treatment heterogeneity across 30 countries may confound exacerbation rates.

Study Type: Retrospective observational cohort study (spatial proteomics/high-plex immunofluorescence)

Key Question: Do EGFR and KRAS mutations differentially shape the spatial immune architecture of the NSCLC tumour microenvironment, and does this architecture carry prognostic significance?

Key Findings:

• EGFR- and KRAS-mutant tumours showed higher tumour cell density and reduced immune infiltration versus wild-type, with depletion of cytotoxic T cells, dendritic cells, and granulocytes in both mutation subtypes
• EGFR-mutant tumours were specifically enriched with clustered M2-like tumour-associated macrophages; KRAS-mutant tumours showed increased T-regulatory cells and TAMs in proximity to tumour cells
• All spatial immune metrics independently correlated with prognosis on Cox proportional hazards modelling

Clinical Relevance: This may explain heterogeneous immunotherapy responses in NSCLC patients — a significant management challenge in UK thoracic oncology — and suggests mutation-specific spatial immune profiling could refine patient selection for immunotherapy.

Limitations: Retrospective design limits causal inference, and clinical outcome data on immunotherapy treatment are not specified.

Study Type: Prospective cohort study (COPDGene registry)

Key Question: Does occupational exposure to dust and/or fumes predict future adverse respiratory, cardiovascular, and other clinical outcomes in smokers?

Key Findings:

• Combined dust-and-fumes exposure (34.4% of participants) was associated with a 38% higher rate of respiratory exacerbations (aRR 1.38, 95% CI 1.26–1.52) versus unexposed individuals
• The same exposure group showed significantly increased odds of atherosclerotic cardiovascular disease (aOR 1.35, 95% CI 1.17–1.56) and pneumonia (aOR 1.39, 95% CI 1.19–1.63)
• Dust-only or fumes-only exposure did not independently produce statistically significant outcome differences; cancer and VTE were not associated with any exposure category

Clinical Relevance: Occupational history is frequently underdocumented in ICU admissions; these findings reinforce the need to elicit occupational exposure when assessing exacerbating factors in critically ill patients with COPD or cardiovascular disease.

Limitations: Reliance on self-reported occupational exposure introduces significant misclassification bias.

Study Type: Clinical practice guideline (systematic review and network meta-analysis informed; GRADE methodology)

Key Question: Which noninvasive respiratory support strategy (HFNC, NIV, or CPAP) should be used in adults with acute hypoxemic or hypercapnic respiratory failure, peri-intubation preoxygenation, and post-extubation support?

Key Findings:

• Acute hypoxaemic failure: strong recommendation for HFNC; conditional recommendation for NIV/CPAP — both reduce intubation rates
• Acute hypercapnic failure: strong recommendation for NIV (mortality and intubation benefit); HFNC conditionally acceptable only if pH >7.25 with close monitoring
• Peri-intubation and post-extubation: strong recommendation for HFNC or NIV pre-intubation; risk-stratified approach post-extubation (HFNC low-risk, NIV high-risk)

Clinical Relevance: Provides the first comprehensive, GRADE-based ATS guideline across the full spectrum of acute respiratory failure, directly informing ICU escalation and weaning decisions relevant to UK critical care practice.

Limitations: Recommendations rely on indirect network meta-analyses; individual patient-level risk stratification remains incompletely defined.

Study Type: Large retrospective cohort study

Key Question: Does nocturnal respiratory effort, measured by oesophageal pressure (PES), independently predict long-term mortality in patients investigated for OSA?

Key Findings:

• In 16,083 patients over 15-year median follow-up, 9.3% died; higher PES quartiles carried increased mortality risk (3rd quartile HR 1.21, 95% CI 1.03–1.43)
• PES remained an independent predictor after adjustment for age, BMI, comorbidities, AHI, and oxygen saturation
• Longer duration spent above higher PES thresholds correlated with progressively greater mortality risk

Clinical Relevance: For UK critical care and sleep medicine clinicians, this suggests AHI and nocturnal hypoxaemia alone may be insufficient risk stratification in OSA — respiratory effort monitoring could identify high-risk patients who would otherwise be missed.

Limitations: Retrospective single-centre design with no data on OSA treatment initiated during follow-up, which may confound mortality outcomes.

Study Type: Network meta-analysis of RCTs

Key Question: Does extended infusion (EI, 2–4h) or continuous infusion (CI, 24h) of beta-lactam antibiotics produce better outcomes than intermittent bolus (IB) in adults with severe infection?

Key Findings:

• Neither EI nor CI significantly reduced all-cause mortality versus IB (EI: OR 0.80, 95% CI 0.55–1.17; CI: OR 0.86, 95% CI 0.62–1.02)
• Both EI and CI significantly improved clinical cure rates versus IB (EI: OR 1.58, CI 1.13–2.23; CI: OR 1.35, CI 1.05–1.85), with EI ranking highest
• EI was associated with borderline reduction in hospital stay (−3.49 days, 95% CI −6.79 to −0.08); CI showed no benefit

Clinical Relevance: Supports current UK critical care practice favouring prolonged beta-lactam infusion strategies, with EI appearing practically advantageous over CI without additional adverse effects.

Limitations: Most included RCTs had moderate-to-high risk of bias, and EI-versus-CI comparisons rely entirely on indirect network evidence with no head-to-head trials.

Study Type: Retrospective observational cohort study

Key Question: Does RBC transfusion acutely improve mixed venous oxygen saturation (SvO₂) in cardiovascular surgical ICU patients, and can pre-transfusion SvO₂ predict this response?

Key Findings:

• Mean SvO₂ change at cohort level was negligible (+0.08 percentage points, 95% CI −0.28 to +0.43; p=0.671) despite a small Hb rise of 0.42 g/dL
• Lower pre-transfusion SvO₂ independently predicted an individual SvO₂ rise ≥5% (aOR 0.89 per 1% increase; AUC 0.778), with an exploratory Youden cutoff of 69%
• Authors explicitly caution this association does not confirm improved tissue oxygenation or clinical benefit

Clinical Relevance: In post-cardiac surgery ICU patients — a common UK tertiary cohort — SvO₂ alone should not be used as a transfusion trigger, reinforcing restrictive transfusion strategies.

Limitations: Single-centre retrospective design limits generalisability, with no clinical outcome data linking SvO₂ response to patient benefit.